TSXV:MBI.H - Post by User
Post by
joe9904on Mar 07, 2014 8:46am
214 Views
Post# 22293325
Just announced
Just announced
Med BioGene Inc. (TSX VENTURE: MBI) today announced the publication in the Journal of Thoracic Oncology of data demonstrating a second, independent validation of the 15-gene signature to be marketed as GeneFx(R) Lung entitled "Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Non-Small-Cell Lung Cancer Including Stage IA Patients." The study validated in a prospective and blinded manner the prognostic accuracy of the GeneFx Lung signature in an independent cohort of 181 early-stage (I and II) non-small-cell lung cancer (NSCLC) tumor specimens in different histologic subtypes.